Skip to main content
. Author manuscript; available in PMC: 2019 Sep 3.
Published in final edited form as: Cell Rep. 2019 Apr 16;27(3):806–819.e5. doi: 10.1016/j.celrep.2019.03.066

Figure 2. Short Schedule of MEKi Treatment Alters T Cell Activation Status Ex Vivo.

Figure 2

(A) Schema of ex vivo short versus long treatment experiment.

(B) CTLA-4, PD1, Ki-67, and 4–1BB expression in CD8+ T cells and CD4+Foxp3 cells by flow cytometry after selumetinib (left) or trametinib (right) treatment for 96 hr. *p < 0.05; **p < 0.01, Welch’s test.

Error bars represent SD. Samples were biological replicates. The experiment was performed twice, and representative results are shown here.